Viking Therapeutics, Inc. — Director's Dealing 2021

Jan 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Viking Therapeutics, Inc. (VKTX)
CIK: 0001607678
Period of Report: 2021-01-04

Reporting Person: Mancini Marianna (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-04	Common Stock, par value $0.00001 per share	A	73000	$0.00	Acquired	167655	Direct
2021-01-04	Common Stock, par value $0.00001 per share	A	6750	$0.00	Acquired	174405	Direct
2021-01-04	Common Stock, par value $0.00001 per share	F	2773	$5.80	Disposed	171632	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-04	Stock Option (Right to Buy)	$5.80	A	90000	Acquired	2031-01-04	Common Stock (90000)	Direct

Footnotes

F1: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject
to the RSU shall vest on each one year anniversary of the grant date of the award.

F2: The reported securities were subject to a performance restricted stock unit award that was granted on January 15, 2019, 33.33% of which vested
on January 4, 2021 upon the achievement of a non-financial performance goal.

F3: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon
the vesting of certain shares of common stock subject to a performance restricted stock unit award.

F4: One-third of the shares subject to the option will vest on each anniversary of the grant date.